GW Pharma in Japan Cannabis Tie-Up (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japan-based Otsuka Pharmaceutical and Britain-based GW Pharmaceuticals have signed a deal to co-develop cannabis medicine for treating cancer and aliments in the central nervous system. Otsuka will invest $9 million into cannabis research over a three year period. Otsuka this year also signed a deal with GW for worldwide development and marketing rights to GW's drug Sativex. (Click here for more